ASX / Media Release

20 November 2026

Results of Meeting

Invex Therapeutics Limited (**Invex**, **ASX:IXC,** or **the Company**) today announces that in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001, the results of the Annual General Meeting held today, 20 November 2026, at 10am at Level 3, 101 St Georges Terrace, Perth WA 6000.

A copy of the proxy and poll results for the resolutions is attached.

- ENDS -

This release dated 20 November 2026 has been authorised for lodgement to ASX by the Company Secretary of Invex Therapeutics Ltd.

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™.

www.invextherapeutics.com.

Results of Meeting

Invex Therapeutics Limited

Annual General Meeting

Friday, 20 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 ADOPTION OF REMUNERATION REPORT	P	21,032,560 98.57%	294,783 1.38%	0	10,000 0.05%	21,042,560 98.62%	294,783 1.38%	0	-
2 RE-ELECTION OF DIRECTOR – PROFESSOR WARREN HARDING AM	P	21,296,613 99.81%	30,730 0.14%	0	10,000 0.05%	21,306,613 99.86%	30,730 0.14%	0	Carried
3 APPROVAL OF 7.1A MANDATE	P	21,214,113 99.42%	113,230 0.53%	0	10,000 0.05%	21,224,113 99.47%	113,230 0.53%	0	Carried